Search results for: 'drug ad dd02'

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

17 Sep 2024  |  Global  |  Market Research

ADAS and AD Sensor Suite Strategies, Europe, 2024 2030

OEMs Strategies Will Drive Transformational Growth by Using LiDAR as a Primary Sensor with Cameras and Imaging Radar to Meet the Rise of Eyes-off Driving

Infographics

×

Key Issues Addressed

The global automotive industry is going through a transformation with the convergence of the connected, autonomous, shared, and electric (CASE) trends. Connectivity and autonomous driving (AD) features are leading this transformation. Globally, OEMs are looking to introduce various advanced driver assistance system (ADAS) features ranging from L0 t...

The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...

Server-side ad insertion has normally been about tackling the problems of ad blocking and device fragmentation. But the industry is now seeing platform shifts that change the sweet spot of ad stitching towards live and catch-up TV. Client-side ad SDKs have grown in sophistication, the platforms they run have become more capable and the transition t...

The conventional drug discovery and diagnostics technologies are unable to cope up with the current disease management practices. To this end, researchers have explored possibilities beyond life sciences. Specifically, they have figured out that the use of engineering principles to biological systems can revolutionize the drug discovery and diagnos...

With the healthcare industry moving toward patient convenience and comfort, pharmaceutical and medical device companies are continuously researching for the most effective, side effect free, convenient route of drug delivery. Transdermal drug delivery is a painless method of delivering drug formulation. Transdermal route of drug administration has ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...

Targeted drug delivery is gaining traction owing toward significant demand for improvement in the drug delivery efficiency as well as the need to mitigate potential side-effects, which can occur due to drug accumulation. The concept of targeted drug delivery is not new, the technology started gaining pace with the advent of nanotechnology and bioco...

01 Mar 2024  |  North America  |  Market Research

Global Orphan Drug Growth Opportunities

Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

Infographics

×

In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...